Tag

89bio

All articles tagged with #89bio

Akero's NASH Treatment Fails, Stock Plummets

Originally Published 2 years ago — by Investor's Business Daily

Shares of Akero Therapeutics (AKRO) and 89bio (ETNB) plummeted after Akero's liver-disease treatment failed to meet expectations in a midstage study. While the drug showed statistically significant results in resolving NASH, the improvement in liver scarring was not statistically significant. Despite this, analysts believe that the effectiveness data sets for both companies are strong, with 89bio potentially pulling ahead due to its dosing schedule and lower side effects. Akero shares fell 64% and 89bio shares tumbled 36.6% as a result of the news.

business healthcare 89bio akero-therapeutics healthcare liver-disease-treatment nash stock-market

NASH Drug Developers 89Bio and ETNB See Promising Results in Mid-Stage Trials

Originally Published 2 years ago — by Endpoints News

89bio's Phase IIb data showed its drug, an analog of FGF21, was better than placebo at lessening fibrosis without worsening NASH in two of three dose groups. The data pave the way for a potential Phase III, following in the footsteps of another biotech in its drug class, Akero Therapeutics. To fund a late-stage study, 89bio "would need to raise additional capital," with the company having about $188 million at the end of last year.

business healthcare 89bio clinical-trial fgf21 healthcare nash phase-ii